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Abstract
While it would provide many advantages from many aspects, the application of continuous mixing processes to the pharmaceutical field is still 
in its infancy. In this paper we report results concerning the continuous mixing of nine ingredients (including three actives) that constitute a current 
drug. We examine these results in the light of different pharmaceutical process constraints, such as mixture quality control, time-stability of this 
quality, sensitivity of the process to perturbations. The apparatus is a pilot plant Gericke GCM 500 continuous mixer with three loss-in-weight 
feeders. A specific experimental protocol is developed to determine the homogeneity of the mixtures at the outlet of the mixer. The homogeneity 
of the mixtures is examined through industrial standards that would allow the product to be released on the market. The steady-state operation 
is first reported on, and it is demonstrated that a very acceptable mixture can be produced under certain conditions, with excellent time stability. 
The response of the mixer to filling sequences of two critical feeders is also quantified in terms of mixture homogeneity. It is found that it may be 
preferable to stop the process during these periods.
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1. Introduction
1.1. General industrial context with special attention to the
pharmaceutical industry
Controlling powder-mixing operations is crucial in practi-
cally all kind of industries: ceramics, agro-food, cement, aromas,
explosives, cosmetics or drugs. By fixing the composition of a
mixture at a desired scale, it will largely guarantee the attainment
of the end-used properties of a product, even if, in most cases,
this scale and/or these properties are not well defined. Chemi-
cal and process engineers (and also product engineers) working
with powders are currently faced with problems associated with
mixture quality. They have to overcome such difficult barriers
as sampling, use more or less advanced statistical analysis, cope
with different standards and practices, but also understand a wide
range of available technologies. Most of the time, when consid-
ering the insertion of a new mixer in an existing process, costly
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pilot or full scale tests need to be performed. As a consequence,
the general tendency in the industry is to avoid any change, and
to concentrate on the way to validate the actual process. This is
illustrated by a certain elasticity in sampling recommendations
and practices [1,2].
With regard to the pharmaceutical industry, the above gen-
eral picture is even magnified. This is especially due to
traceability needs and quality insurance. When transposed to
a mixing problem, these requirements can be broken down
into:
• Qualification of the components. These must have been pre-
viously characterised from the point of view of purity, particle
size, density, etc.
• Operational qualification regarding the training of the opera-
tors.
• Qualification of the operations. Each operation in the process
must have been validated separately (mixer, feeders, etc.).
Normally, this is the task of the equipment manufacturer.
• Process qualification is the responsibility of the producer.
It must demonstrate that a process will give the product
the desired homogeneity, and may rely on optimal process
conditions, but also on sampling procedures and analytical
protocols.
• Washing validation procedures. This is essential to avoid
cross-contamination and generally concerns the analysis of
the washing effluents.
This requires validation step-by-step, unit operation by unit
operation. It also means that a single change in a single opera-
tion requires resetting the validation of the following steps, and
sometimes of the previous ones. While this is essential for prod-
uct quality and sanitary rules, it is a clear handicap for process
innovation in this field.
The “reconciliation principle”, which serves as the basis for
traceability, also forms part of such necessary but restricting
controls. This principle states that the flow of all the compo-
nents of a mixture entering a process may be superior or equal
to the flow leaving this process. In other words, if losses may
be explained, they cannot be found in another batch. Also, if a
mixture is found to be inhomogeneous, the whole related pro-
duction must be destroyed. Even if there is clearly not a problem
of product contamination by an external source, it will not be
permitted to mix the powders again. This is in contradiction with
basic process optimisation principles that are currently taught to
young chemical engineers and demonstrates the main difficulty
that a pharmaceutical company is currently faced with: how to
stay competitive when process optimisation encounters so many
constraints?
1.2. Mixture quality and pharmaceutical standards
First of all, the quality of a powder mixture cannot be defined
if there is no precision on the scale at which the mixture is
observed. If this scale is the entire production, the whole batch,
mixture quality is irrelevant. Conversely, if it is a single particle
of a binary mixture, mixture quality will be zero. Normally,
this scale of scrutiny corresponds to that of the unit dose that a
patient may take. . . something between 10 mg and 5 g in typical
human recipes. When compared to the size and filling of an
industrial mixer, this means that it may contains from several
hundreds of thousands to one or two millions times the unit
dose.
Secondly, one may identify what the component is for which
the mixture has to be qualified. This key component is logi-
cally the active ingredient, of therapeutic effect. But in the case
of multiple key components, what follows must be repeated for
each “active”. If a mixture is composed of N unit doses, therefore
corresponding to one batch or a definite period of time in con-
tinuous operation, then mixture homogeneity will be expressed
by the variance or standard deviation σ in the composition in
active xi of all the doses, with respect to the mean content µ:
σ2 = 1
N
N∑
i=1
(xi − µ)2. (1)
However, due to the difference in scale explained above, and
because in-line and non-destructive methods are not well devel-
oped up to now, it is not feasible for a real pharmaceutical case to
use this formula at “full scale”. Sampling procedures are there-
fore used to approach this criterion by taking n samples out of
the N possible, thus defining:
s2 = 1
n
n∑
i=1
(xi − xm)2 (2)
where xm is the mean content of active ingredient in the samples.
Finally, because a standard deviation has a real significance if
it is compared to the mean value, the coefficient of variation is
often employed:
CV = s
xm
. (3)
This overall analysis, including the sampling impact, serves
as a basis for the definition of standards that need to be met to
avoid the production being destroyed, with all the resulting cost
implications. Basically three criteria are under observation:
• The mean of the samples xm. Even if there is always a sam-
pling error, a significant difference from the “true” mean µ
can be indicative of a bad mixture. A typical criterion attached
to this is: µ − 7.5% µ< xm <µ+ 7.5%µ.
• The individual values. A unit dose must contain the theoret-
ical active composition with a certain tolerance. In practice:
µ − 15% µ< xi <µ+ 15%µ. So in a tablet containing 1 g
of paracetamol, one may expect to have between 850 and
1150 mg of the active.
• The coefficient of variation. It must be inferior to 6%. In pro-
cess development, CV’s of around 1 or 2% are the objectives
to reach so as to limit the risk of homogeneity loss during
scale up.
Some differences can also be appreciated if one compares
US Federal Drug Administration (FDA) and EU standards. For
example, the rule cited above for the individual values is used in
the EU pharmacopoeia. However, the FDA does not mentioned
the true mean µ as the reference for calculating the range of
the permitted values, which means that this can be done with
estimated mean xm. In this case, the FDA standard is less severe
that the EU one.
In parallel to the existence of these criteria for “batch libera-
tion”, one may also be confronted with real practice. As stated
above, sampling must be done at the scale of scrutiny, which
means the scale of, say, one tablet. If this can be done eas-
ily at the end of the process, it is not always feasible at that
precise scale for the previous steps, including the mixing step,
mainly because of sampler size and process accessibility (also
resulting in higher sampling errors). This motivated the initiative
of developing Process Analytical Technologies (PAT), as on-
line methods that are well adapted to detecting pharmaceutical
molecules: NIR spectroscopy [3], FT-Raman [4], laser-induced
fluorescence [5,6].
Table 1
Main characteristics of the powders used and mixing configuration
Mean particle size
(!m)
Carr index (%) True specific gravity
(g cm− 3)a
Theoretical weight per
unit dose (g)
Mixing configuration Mass flows (kg/h)
BM containing A1
and A2
110b 15 1.48 4.275 BM 32.87
A3 28c 21 1.22 0.025 A3 + 1/2 I1 0.95
I1 67c 15 1.31 0.200
I2 59c 11 1.33 0.050 I3 + I2 + 1/2 I1 4.18
I3 53c 20 1.75 0.400
a Measured by Helium pycnometer.
b Measured by sieving.
c Measured by laser diffraction.
1.3. Batch versus continuous in the pharmaceutical
industry
Recently, Pernenkil and Cooney [7] published a very com-
plete review of continuous powder-mixing, some 30 years after
the first one written by Williams [8]. They pointed out the little
attention that the scientific literature has paid to continuous pro-
cesses for mixing powders and grains, particularly with respect
to batch processes. They also noted the absence of reported work
concerning the continuous mixing of pharmaceutical powders.
To our knowledge, the effective use of continuous mixers (as well
as continuous granulators) in pharmaceutical plants is restricted
to four or five examples throughout the world. Indeed, the batch
reference predominates to an extent which is somewhat “cul-
tural” in this field of activity, while in many cases, replacing an
old batch mixer by a continuous one would result in a significant
increase in productivity.
Basic advantages of continuous mixers with respect to batch
mixers are currently:
• Lower size of the mixing vessel for a same production level.
• Less segregation risk due to the absence of handling opera-
tions, such as filling and emptying.
• Lower running costs.
• Better definition of mixture homogeneity, at the outlet of the
apparatus.
In the pharmaceutical context, we may add and emphasize:
• The possibility to include an on-line analysis set-up at the
outlet of the mixer to measure the quality of the mixtures, but
also to implement process control. This point is exactly in the
direct line of the PAT recommendations.
• The fact that practically all the final steps, such as tabletting
and conditioning, in a drug fabrication scheme are already
continuous operations.
• The elimination of scale-up problems during process devel-
opment.
This last point is undoubtedly a very serious advantage for
continuous mixers. The validation of an industrial “batch” dur-
ing process development must actually be done at a scale of
1/10 of the real batch capacity. This means that if one wants
Fig. 1. Pilot plant equipment (a) used showing the loss-in-weight feeders, and
stirring device (b).
to produce 100 kg at industrial scale in a batch mixer, the val-
idation can be done with a mixer containing 10 kg of mixture.
In continuous mixing, this may be traduced by 1 h of full scale
test to represent 10 h of industrial production. The risk of error
is undoubtedly much easier to assume for a continuous process
rather than for a batch process that has to “cross the scales”.
In this paper, we will report and discuss, probably for the
very first time, some results that we obtained when studying
a “real” pharmaceutical mixture of 9 ingredients including 3
actives. First, we will present the continuous mixer used and the
specific methodologies developed. Then, we will focus on the
homogeneity of the mixtures produced and their time-stability in
normal operation. To continue with process constraints, we will
also examine the effect of process disturbance, such as periods
of feeding of the loss-in-weight feeders.
2. Experiments
2.1. Mixture considered
The industrial case under consideration is a drug currently
on the market containing 3 actives for a total of 9 ingredients.
Two of the actives, which will be referred to as A1 and A2, are
agglomerated with three other ingredients to form a basic mix-
ture (BM). A1 will represent 10% (by weight) of the final drug,
while A2 will concern 4% of it. The four last ingredients, three
additives I1, I2, I3 and the active A3, are divided into two pre-
mixes P1 and P2, which are defined in Table 1, as well as some
other characteristics.
This finally defines a mixture made of three streams to mix:
BM, P1, P2. The flow rates attached to these streams have been
calculated to cope with the industrial cadences of production,
Fig. 2. Photograph of the outlet of the mixer showing the sampling set-up.
and of course, with the composition of the mixture. As it can be
seen from Table 1, the overall mixture is of low dosage concern-
ing the active A3 (nearly 0.5%), which can be considered as the
“main key component”. However, the mass of A3 in a sample of
unit size is still detectable by conventional methods. As regards
the “physical” differences of the ingredients, the values do not
really indicate an important risk of particle segregation by size
or density. We may only remark that flowability is worse for A3
and I3, which are to be considered as fully cohesive powders and
may result in difficulties during dosage and mixing.
2.2. Mixing equipment and experimental procedure
The mixer used is a Gericke GCM 500® nearly hemi-
cylindrical apparatus of the following dimensions: 50 cm long,
Fig. 3. Mixtures obtained after different operation times under the conditions specified on the graphs, showing the values of the individual content and the mean
content in A3, as well as the related coefficients of variation.
20 cm diameter (see Fig. 1). The stirrer consists of 15 blades
mounted on a driven shaft. The range of rotational speeds of
the stirrer varies from 10 to 160 rpm, and may be advanta-
geously described by a Froude number Fr = RN2/g, where R
is the radius of the mobile and N its rotational speed. In pre-
vious studies [9–11], it has been shown that Froude values
below 1 corresponded to dense phase flow, while Froude val-
ues superior to 1 corresponded to nearly fluidised motion of the
particles.
Three loss-in-weight feeders of different capacities and char-
acteristics ensure a very acceptable regularity and precision of
dosage. Qualification of these feeders for the present products
was made in a preliminary study, which is not reported here for
clarity and confidentiality reasons.
To qualify the mixtures produced, a sampling protocol was
specifically established. Striated boxes defining well separated
sections were placed on a conveyor belt of variable speed located
at the outlet of the mixer (see Fig. 2). The speed of the belt
was adjusted so that the powder mass falling in a section cor-
responded to the scale of scrutiny of the mixture (nearly 5 g).
While a certain fluctuation exists of the sample masses collected
through this procedure, this error was neglected because the
analysis of mixture homogeneity is based on the concentrations
of the actives (and mainly A3).
For homogeneity calculations, 10 consecutive samples were
collected and the composition in each active component was
calculated after an industrially validated dissolution and HPLC
specific protocol. The three criteria defined in the introduc-
tion of this paper were used to determine the best conditions
of operation of the mixer (stirrer type, rotational speed, pre-
mix configuration). This “optimisation” procedure is not the
objective of the present work and will be reported in future
communications.
Fig. 4. CV and mean content in A3 obtained after 10 min of operation for
different rotational speeds.
3. Mixture quality in steady-state operation
Because the active A3 is low-dosed in the mixture, we will
concentrate our efforts on describing the homogeneity regarding
this component. Fig. 3 reports the results of the sampling pro-
cedure described above for a stirrer rotational speed of 50 Hz
and for several tries corresponding to different operation times.
In the graphs, the tolerance intervals corresponding to the mean
and to the individual values are also specified.
As can be seen from Fig. 3, no individual value is outside
the tolerance interval, the sample mean lays in the acceptable
range and the CV values are much below the limit of 6%. After
10 min running, which may be considered as corresponding to
five times the mean residence time of the particles, the mix-
ture passes the three criteria for drug “liberation”. In addition,
it seems that the mixture quality with respect to A3 improves
with the time of operation of the process. This may be due to
Fig. 5. Transitory regimes associated with a change in dosage mode.
a micromixing effect generated by the cohesive nature of the
components. A3 is a cohesive powder which is made of “pack-
ets” of particles. These packets need a certain time to disrupt
inside the mixer and disperse into the bulk, therefore improv-
ing the quality of the mixture. This may concern the particles
that stay longer in the mixer, those belonging to the tail of a
Residence Time Distribution curve. For instance, the micromix-
ing steady-state characteristic time may be somewhat higher
than the macromixing time (the well-known “5 mean residence
times” rule). This also suggests that a better premix of A3 with
I1, would result in a better final mixture. For this kind of mixing
problem, there is also no doubt that a random sampling protocol
would have been very suitable for deriving the homogeneity of
the mixtures.
In the above, the rotational speed was fixed to 130 rpm (or
50 Hz for the engine), which corresponds to Fr = 1.89. In this
nearly fluidised regime, we also performed experiments with
a lower and a higher rotational speed (see Fig. 4). While the
other two values of the rotational speed (namely 40 and 60 Hz)
still provided mixtures of industrially acceptable quality, they
also gave rise to higher CV’s and mean values that were quite
different from the “hoped value” 25 mg. It may also be noted that
experiments performed in the dense phase flow regime (below
35 Hz), and not reported here, produced much worse mixtures
and sometimes non-validated mixtures from the viewpoint of
the present standards. Indeed, the choice (but also design) and
the operation of mixing equipment to resolve a specific mixing
problem is a very tedious task, as it still requires empiricism in
the optimisation procedure.
4. Impact of changes in dosage modes
Loss-in-weight feeders lose their regularity and precision
when the mass of powder in the hopper becomes less than
approximately 15–20% of its apparent volume. This means that
such feeders may also be fed during processing, either through a
storage tank with an aerolic conveyor or from a volumetric feeder
of high storage capacity. This results in an important source of
mixture homogeneity perturbation because during the time ded-
icated to the filling of a loss-in-weight feeder, the powder mass
in the hopper changes too quickly to be counterbalanced by a
change of speed of the feeding screw that may have been able
to ensure the same regularity and precision as before. In other
words, a change of dosage mode, from gravimetric to volumet-
ric, is operated and results in a transitory regime in the mixer
(see Fig. 5). In this last part, we will examine how this problem
affects the quality of the mixtures under consideration.
The experimental protocol consists in: (a) measuring the
mixture quality after 10 min of normal operation; (b) feeding
a loss-in-weight feeder for approximately t0 = 1 min; (c) mea-
suring the mixture quality during the perturbation, after 1 mean
residence time (<t>); (d) measuring the mixture quality after
5 mean residence times. Therefore, we assume that the main
impact of the perturbation on the quality of the mixture corre-
sponds to the powder mix produced at t0 + <t>.
Fig. 6 shows the three mixtures obtained before, during, and
after feeding of the feeder containing A3. As the flow rate asso-
Fig. 6. Mixtures obtained when filling the loss-in-weight feeder of active ingre-
dient A3.
ciated with this feeder is quite low in comparison to the feeder
containing the other two actives, the mixture quality will still be
judged on the basis of the A3 content in the sample.
The mixture produced during this critical phase is not in con-
formity with industrial standards, either from the viewpoint of
the coefficient of variation or from the individual values, while
the sample mean is still acceptable. Fortunately, there is a clear
stability of the process, as the mixture examined after this phase
conforms to these criteria again. In particular, the value of the
CV’s after and before feeding are extremely close to each other,
and also to the value found in Fig. 3. This indicates a cer-
tain reproducibility of the process, as well as demonstrating the
sensitivity of our experimental approach.
Because this feeding operation is only to be repeated one or
twice during the whole production cycle, a possibility – given
that it cannot be recycled – is to destroy the mixture produced
during this specific period of time. But if the cost of doing so
is too high, the process may be stopped during re-feeding. This
problem arises again in Fig. 7, where the impact of similar exper-
iments performed for the loss-in-weight feeder dedicated to BM
(which contains A2 and A1) is shown for each of the three active
ingredients. While A1 and A3 are practically insensitive to the
perturbation, which is logical as A1 is the higher dosed compo-
Fig. 7. Changes in mixture qualities with respect to each active ingredient when
feeding the loss-in-weight feeder containing the basic mixture.
nent and A3 is fed by another feeder, the coefficient of variation
with respect to A2 approaches 8% and the overall mixture is not
validated.
Because the main flow rate is supported by this feeder, this
systematic perturbation will occur quite often (10–15 times
during a production cycle). For instance, it may probably be
advisable to stop the process at a definite time of operation in
order to fill all the feeders. Fortunately, stop-and-go tests (not
reported here) in which the mixer was stopped for between 1 min
and several hours and then started again, have been shown to have
no influence on mixture quality. Nevertheless, an intermediate
storage of a small volume (a buffer) after the continuous mixer
will be necessary, at least for this reason.
5. Concluding remarks
In this paper, we have oriented the presentation of our results
towards the “normal” operation of a continuous mixer operat-
ing with pharmaceutical products, and examined the quality of
the mixtures using industrial standards. We did not fully report
other results concerning the influence of operating parameters,
the impact of accidental perturbations, the procedures for the
beginning and the end of the process, in particular to take account
of reconciliation principles. This will be done in future papers.
Also, we may emphasise that the consideration of various key
components in the mixture is undoubtedly an additional diffi-
culty: as in the present case, the risk is to invalidate the mixture
because of one “indicator” out of nine.
While for the specific case under study, very acceptable con-
ditions have been found to industrialise the process in the actual
configuration, there are still many improvements to bring:
• The improvement of mixer design, at many levels: design of
the inlet of the mixer to premix the ingredients in the chute;
design of the outlet of the apparatus to adjust the mean res-
idence time; design of the stirrer to approach the perfectly
mixed vessel; . . .
• The inclusion of process constraints, such as facility of dosage
of certain ingredients, during the formulation stage. It would
be a pity to give up so important a process optimisation scheme
as changing from batch process to continuous process, just
because a single additive was chosen rather than a different
one.
• The development of an on-line and real-time technique, with
a fully validated associated methodology, for measuring the
homogeneity of the mixtures. This would in turn open the
door to process control.
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Appendix A. Nomenclature
CV coefficient of variation of a mixture
Fr Froude number
g acceleration of gravity (m s− 2)
n number of samples in an estimation
N number of possible samples in a mixture
R radius of the stirrer (m)
s2 variance of a mixture (estimated from sampling)
t0 feeding time (s)
<t> mean residence time (s)
xi composition of sample i in key component
xm mean composition in key component (estimation)
Greek letters
µ mean composition in key component (real)
σ2 variance of a mixture (estimated from sampling)
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